Amylyx Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
AMLX$30.21+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $229,136 | $226,651 |
| Marketable securities | 50,632 | 90,328 |
| Prepaid expenses and other current assets | 5,256 | 6,692 |
| Total current assets | 285,024 | 323,671 |
| Property and equipment, net | 212 | 310 |
| Restricted cash equivalents | 986 | 985 |
| Operating lease right-of-use assets | 4,881 | 5,181 |
| Other assets | 2,500 | 2,498 |
| Total assets | $293,603 | $332,645 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,529 | $3,519 |
| Accrued expenses | 11,282 | 17,910 |
| Operating lease liabilities, current portion | 1,155 | 1,259 |
| Total current liabilities | 15,966 | 22,688 |
| Operating lease liabilities, net of current portion | 4,476 | 4,698 |
| Total liabilities | 20,442 | 27,386 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 and 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized; 111,026,477 and 109,884,502 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 1,065,621 | 1,056,271 |
| Accumulated deficit | (792,711) | (751,427) |
| Accumulated other comprehensive income | 240 | 404 |
| Total stockholders’ equity | 273,161 | 305,259 |
| Total liabilities and stockholders’ equity | $293,603 | $332,645 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.